A 'meeting of minds' and the risk of not being able to 'unknow' information

"The introduction of new clinically evaluated treatment options will support healthcare professionals in managing the growing burden of chronic metabolic conditions,” said Manny Simons, General Manager, Lilly New Zealand.

Twelve months after the Albanese Government announced its $792.9 million women’s health package, new data shows significant uptake of subsidised medicines and expanded access to Medicare-funded services for women across Australia.

ViiV Healthcare Australia has marked another milestone in its long-running commitment to community-led HIV responses, awarding $200,000 to six organisations through its annual Positive Action Community Grants program.

Mark Butler’s four 'pillars' on medicines policy and the argument that Australia prioritises low prices over preventing shortages and ensuring access. Do we need smarter, targeted incentives to address shortages that often reflect global challenges? Is there a risk of 'process creep' that actually slows access? Aged-care reforms that unintentionally removed funding for dose administration aids and glucose monitoring.

New research commissioned by the Pharmacy Guild of Australia suggests that growing frustration with long GP wait times is pushing men to seek care elsewhere, with community pharmacies increasingly filling the gap.

The speculation of a proposed pre-negotiation memorandum of understanding between the two manufacturer groups can be interpreted as further evidence of planning.

At the top of the field, GSKlimbers have established themselves as the current frontrunners with over $22,000 already raised.

Early examples appear designed to attract attention. High-profile medications, such as GLP-1 weight-loss therapies, are advertised with steep discounts. 

In 2025, nearly 100,000 cases and more than 300 flu-related deaths were recorded in Queensland. Most hospitalisations and deaths were among unvaccinated people.

Artificial intelligence is no longer a future concept in healthcare. It will be the focus of an upcoming breakfast in Sydney, bringing together pharmaceutical and healthcare executives to examine how AI can be adopted while regulatory frameworks continue to evolve.

Australia's complex federation creates a 'status quo' bias on policy. This is particularly true in health. Major reform is very difficult beyond financing changes that often buy time and delay problems.

At a summit hosted by the Generic and Biosimilar Medicines Association in Canberra yesterday, Australia’s political and policy leaders warned that the nation’s medicines system is approaching a critical inflection point.

In his opening address, Health Minister Mark Butler equated HTA reform with ensuring supply and identified both as core priorities in his agenda, clearly signalling the terms of engagement for an upcoming negotiation.

Australia’s nuclear medicine sector is urging the Commonwealth to establish a dedicated national funding stream for radiopharmaceutical cancer therapies

Pfizer has reported encouraging mid-stage clinical results for an experimental once-monthly injectable obesity treatment, strengthening its push into one of the most competitive and fast-growing areas of global pharmaceuticals.

The industry has every right to highlight the wording of its agreements in pushing for any new negotiation beyond the May Budget, but it is critical that it considers history and some complex realities.

Australians living with rare and less common cancers are facing significantly greater gaps in care and support than those diagnosed with more common cancers, according to new national survey findings released to mark World Cancer Day.

The association has called on the Federal Government to use the 2026–27 Budget to reverse Australia’s growing lag in access to innovative medicines, warning that patients are increasingly missing out on treatments already available overseas.

AusBiotech and Medicines Australia have established a joint Advanced Therapies Advisory Group to help shape the future of cell and gene therapies in Australia.

JAFA is now seeking a new CEO to build on Angela McKay's achievements, lead the organisation into its next phase, and advance its strategic priorities.